Kinaset Therapeutics
Kinaset Therapeutics Raises $103M Series B | Inhalable JAK Inhibitor for Asthma
Kinaset Therapeutics Closes $103M for Asthma Drug
Kinaset Therapeutics, developing an inhalable pan-JAK inhibitor for severe asthma, has raised $103 million in Series B funding.
The round was co-led by RA Capital Management and Forge Life Science Partners with participation from EQT Life Sciences, Vivo Capital, and Schroders Capital.
Key Highlights
- Inhalable pan-JAK inhibitor (frevecitinib)
- Targets severe asthma patients
- Minimal systemic side effects
Company Overview
Kinaset Therapeutics is developing frevecitinib, an inhalable pan-JAK inhibitor designed to target lung inflammation in severe asthma patients while minimizing systemic effects.
Company Info
Investors (4)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free